Improving CART19 function by targeting a membrane-proximal CD19 epitope with fast on- and off-rates. Early results for the Penn Medicine-developed AT101 presented at ASH Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response
In an article published in the Journal of Applied Physiology, researchers at the University of São Paulo show that damage to small blood vessels in the lungs caused by SARS-CoV-2 is the main factor underlying severe COVID-19. Blood clotting (thrombosis) in the capillary vessels of the lungs is one of the first consequences of severe COVID-19,
The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an
